Monday, July 26, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Endometrial and Cervical Cancers

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Monday, July 26th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Mansoor Raza Mirza, MD
Medical Director
Nordic Society of Gynaecological Oncology – Clinical Trial Unit
Chairman, European Network of Gynaecological Trial Groups
Faculty Member, European Society of Gynaecological Oncology
Chief Oncologist
Copenhagen University Hospital
Copenhagen, Denmark

David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and The James Cancer Center
Columbus, Ohio

Angeles Alvarez Secord, MD, MHSc
Professor, Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.

Endometrial Cancer (EC)

  • Incidence of high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in patients with advanced EC; current indications for MSI/MMR testing
  • Efficacy and safety outcomes with pembrolizumab monotherapy for patients with MSI-high (MSI-H)/MMR-deficient (dMMR) advanced EC
  • Mechanism of action of dostarlimab; design of the Phase I/II GARNET trial evaluating dostarlimab for patients with advanced EC
  • Available safety and efficacy data from GARNET: Response rates, duration of response and recent FDA approval of dostarlimab for patients with MSI-H/dMMR tumors
  • Response rates with dostarlimab for patients with microsatellite-stable tumors in the GARNET study; potential clinical role of dostarlimab
  • Key efficacy and safety findings from the Phase II KEYNOTE-146 study assessing pembrolizumab with lenvatinib for relapsed/refractory (R/R) EC; differences in response rates between patients with and without MSI-H/dMMR disease
  • FDA approval of pembrolizumab/lenvatinib for patients with advanced EC that is not MSI-H/dMMR who experience disease progression after prior systemic therapy but are not candidates for curative surgery or radiation therapy; optimal integration of this regimen into clinical practice
  • Incidence and severity of toxicities associated with pembrolizumab/lenvatinib; reported rates of fatigue, hypertension, gastrointestinal toxicity, hand-foot syndrome, hemorrhage, et cetera; dose reduction, discontinuation and other management strategies
  • Similarities and differences in the design, eligibility requirements and primary and secondary endpoints of the Phase III KEYNOTE-775 and LEAP-001 trials comparing pembrolizumab/lenvatinib to standard chemotherapy for newly diagnosed or recurrent advanced EC
  • Current understanding of the effect of combining chemotherapy with immune checkpoint inhibitors
  • Design, eligibility criteria and key efficacy and safety endpoints in ongoing Phase III trials evaluating carboplatin/paclitaxel with or without dostarlimab or pembrolizumab for patients with recurrent or primary advanced EC

Cervical Cancer (CC)

  • Current indications for and timing of PD-L1 testing for patients with advanced CC; definition of PD-L1 positivity based on the combined positive score and its implications for treatment decision-making
  • Available research data with pembrolizumab for patients with recurrent CC; impact of PD-L1 positivity on outcomes
  • FDA approval of pembrolizumab for advanced CC; patient selection and integration into clinical algorithms
  • Spectrum and management of toxicities with pembrolizumab for CC
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III EMPOWER Cervical-1 trial evaluating cemiplimab versus investigator’s choice of chemotherapy for platinum-refractory metastatic CC
  • Incidence and severity of toxicities reported with cemiplimab in the EMPOWER Cervical-1 trial
  • Biologic rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway
  • Response rates, efficacy and safety data with the combination of balstilimab and zalifrelimab for metastatic CC; FDA fast track designation and potential clinical role for this regimen
  • Design, eligibility criteria and key efficacy and safety endpoints of ongoing trials evaluating anti-PD-1/PD-L1 antibodies for advanced CC (eg, CALLA, KEYNOTE-826)
  • Available clinical research data with tisotumab vedotin for relapsed/refractory CC (innovaTV 201 trial); FDA priority review status and potential clinical role
  • Spectrum and incidence of adverse events with tisotumab vedotin; recommended algorithms for the prevention and management of ocular side effects
  • Design, eligibility criteria, and key efficacy and safety endpoints being evaluated in the pivotal Phase II innovaTV 204 study of tisotumab vedotin monotherapy for recurrent and/or metastatic CC; other ongoing research with tisotumab vedotin

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

Learning Objectives

  • Review available data with anti-PD-1/PD-L1 antibodies for patients with microsatellite instability (MSI)-high and microsatellite-stable recurrent endometrial cancer, and appreciate ongoing research attempting to define the role of these agents in the treatment of this disease.
  • Consider the FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial cancer that is not MSI high or mismatch repair deficient who have experienced disease progression after systemic therapy, in order to optimally integrate this novel regimen into clinical management algorithms.
  • Appraise available and emerging research findings supporting the use of immune checkpoint inhibitors for progressive metastatic cervical cancer, and identify patients appropriate for treatment with these agents in or outside of a clinical research study.
  • Recognize the incidence of tissue factor expression in patients with cervical and other gynecologic cancers, and consider emerging pivotal research findings with and the potential role of tisotumab vedotin in therapy for recurrent cervical cancer.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with immune checkpoint inhibitors in the management of endometrial and cervical cancer in order to support quality of life and continuation of therapy.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for patients with gynecologic cancers, and counsel appropriate individuals about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc and Merck.